Whitehall-Robins
This article was originally published in The Tan Sheet
Executive Summary
Association between cough products - "including Robitussin CF" - and increased risk of lung infection or airway blockage "has not been scientifically established," OTC marketer declares in response to August Consumer Reports on Health article. CR review of OTC safety noted Whitehall's product does not carry label warnings on possible risk (1"The Tan Sheet" Aug. 13, In Brief). "Any reported link between cough products and lung infection/airway blockage is anecdotal at best," Whitehall maintains, adding it is "unfair and misleading to single out Robitussin CF as potentially causing these complications." Firm also defends warning language on Advil Cold & Sinus, which was cited by CR
You may also be interested in...
OTC safety
Whitehall-Robins' Robitussin CF labeling does not indicate OTC may increase risk of lung infection and airway blockage, while Advil Cold & Sinus labeling fails to note it may reduce effectiveness of certain antihypertensive drugs, according to August Consumer Reports On Health review of OTC drug safety. Article advises consumers be cognizant of side effects, over-dosing, misdiagnosing, allergies and drug interactions, noting "nearly every OTC drug poses some risks, especially when taken too often, in high doses or with the wrong food, drinks or medications." CR notes exceeding heartburn drug dosage can cause agitation, confusion; acetaminophen overdoses can lead to liver poisoning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands